Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic

Torres, Tiago; Puig, L.

doi:10.1007/s40257-020-00514-2

Cited by 64 publications

(70 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patients continued their oral and topic medications [19] and we have not observed an exacerbation of the disease. Even if there is no available evidence that supports discontinuation of immune-modulating treatments in cutaneous immune-mediated disease because of the risk of COVID-19 [20], we decided to stop adsorptive cytapheresis treatments in all Hidradenitis Suppurativa patients.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy

Colpo

Astolfi²,

Tison

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

The recent Coronavirus Disease 2019 (COVID-19) outbreak has led to profound and rapid changes in the Italian and Veneto Region Healthcare System. This context also includes the quick reorganization which the Apheresis Unit (AU) of the Padova University Hospital, i.e. the Regional Reference Center for Therapeutic Apheresis (TA), had to face. Material and Methods: The study retrospectively evaluated the TA activity (procedures performed, patients treated and consultations) during the COVID-19 pandemic, from March to April 2020, comparing the activity in the same time period in 2018 and 2019. Results: In the period analyzed, a significant reduction in both the total number of procedures performed and of patients treated, respectively by 17 % and 16 % for the procedures and by 19 % and 20 % for patients treated compared to the same period of 2018 and 2019, respectively, was observed. A concomitant reduction in requests for TA consultation for new patients (both outpatients and inpatients) was observed, equal to 32 % and 21 % compared to 2018 and 2019, respectively. Conclusion: Many reasons determined the observed reduction in the TA activity during the recent COVID-19 outbreak. The AU itself was quickly reorganized in terms of location and supplies to allow for the appropriate COVID-19 patients care. Many non urgent cases, after multidisciplinary discussion between Clinicians and Apheresis Specialists, were deferred, maintaining close phone and e-mail contact with patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy

Colpo

Astolfi²,

Tison

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

show abstract

“…There is no data that Dupilumab can somehow increase the risk of SARS-CoV-2 infection, and it can also be done subcutaneously at home. Starting a new therapy with Dupilumab should be considered with extreme caution, while it is advisable to continue an ongoing therapy [27,28] regularly. The British Association of Dermatologists has provided a grid for healthcare professionals to identify patients for whom COVID-19 poses a higher risk due to their disease and treatment.…”

Section: Atopic Dermatitismentioning

confidence: 99%

Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic

Cardinale

Ciprandi

Barberi³

et al. 2020

Ital J Pediatr

View full text Add to dashboard Cite

The COVID-19 pandemic has surprised the entire population. The world has had to face an unprecedented pandemic. Only, Spanish flu had similar disastrous consequences. As a result, drastic measures (lockdown) have been adopted worldwide. Healthcare service has been overwhelmed by the extraordinary influx of patients, often requiring high intensity of care. Mortality has been associated with severe comorbidities, including chronic diseases. Patients with frailty were, therefore, the victim of the SARS-COV-2 infection. Allergy and asthma are the most prevalent chronic disorders in children and adolescents, so they need careful attention and, if necessary, an adaptation of their regular treatment plans. Fortunately, at present, young people are less suffering from COVID-19, both as incidence and severity. However, any age, including infancy, could be affected by the pandemic. Based on this background, the Italian Society of Pediatric Allergy and Immunology has felt it necessary to provide a Consensus Statement. This expert panel consensus document offers a rationale to help guide decision-making in the management of children and adolescents with allergic or immunologic diseases.

show abstract

“…Dust cells, which are present in the alveolar region of lungs, are macrophages that play an important role in CSS. Type I IFN low levels are common to COVID-19, MERS, and SARS which could suppress Th1, but favor Th2 responses [19].…”

Section: Sars-cov-2 Cytokine Storm Syndrome and Organ Failurementioning

confidence: 99%

Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19

et al. 2020

View full text Add to dashboard Cite

Since the first case reports in Wuhan, China, the SARS-CoV-2 has caused a pandemic and took lives of > 8,35,000 people globally. This single-stranded RNA virus uses Angiotensin-converting enzyme 2 (ACE2) as a receptor for entry into the host cell. Overexpression of ACE2 is mainly observed in hypertensive, diabetic and heart patients that make them prone to SARS-CoV-2 infection. Mitigations strategies were opted globally by the governments to minimize transmission of SARS-CoV-2 via the implementation of social distancing norms, wearing the facemasks, and spreading awareness using digital platforms. The lack of an approved drug treatment regimen, and non-availability of a vaccine, collectively posed a challenge for mankind to fight against the SARS-CoV-2 pandemic. In this scenario, repurposing of existing drugs and old treatment options like convalescent plasma therapy can be one of the potential alternatives to treat the disease. The drug repurposing provides a selection of drugs based on the scientific rationale and with a shorter cycle of clinical trials, while plasma isolated from COVID-19 recovered patients can be a good source of neutralizing antibody to provide passive immunity. In this review, we provide in-depth analysis on these two approaches currently opted all around the world to treat COVID-19 patients. For this, we used "Boolean Operators" such as AND, OR & NOT to search relevant research articles/reviews from the PUBMED for the repurposed drugs and the convalescent plasma in the COVID-19 treatment. The repurposed drugs like Chloroquine and Hydroxychloroquine, Tenofovir, Remdesivir, Ribavirin, Darunavir, Oseltamivir, Arbidol (Umifenovir), Favipiravir, Anakinra, and Baricitinib are already being used in clinical trials to treat the COVID-19 patients. These drugs have been approved for a different indication and belong to a diverse category such as anti-malarial/anti-parasitic, anti-retroviral/ anti-viral, anti-cancer, or against rheumatoid arthritis. Although, the vaccine would be an ideal option for providing active immunity against the SARS-CoV-2, but considering the current situation, drug repurposing and convalescent plasma therapy and repurposed drugs are the most viable option against SARS-CoV-2. Keywords Cytokine storm syndrome • ARDS • Rheumatoid arthritis • Herd immunity • Vertical transmission • Vaccine nationalism COVID-19 and SARS-CoV-2 virus An infectious disease COVID-19 caused by a virus belongs to the Coronaviridae family was first reported in December 2019 in the Wuhan city of China. Several other lethal viruses such as Severe Acute Respiratory Syndrome-related Coronavirus (SARS-CoV) and Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) also belong to this family. The SARS-CoV is a single-stranded, enveloped positive-sense strand RNA virus with a genome size between 27 and 34 kilobases that is comparatively larger than other RNA viruses. SARS-CoV-2 driven endemic unfurled into

show abstract

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic

Cited by 64 publications

References 36 publications

Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy

Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy

Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic

Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19

Contact Info

Product

Resources

About